Pastelín HG, Rosas PM

Language: Spanish
References: 8
Page: 172-174
PDF size: 81.18 Kb.

ABSTRACT

Inflammatory status is involved in the pathophysiology of several cardiovascular disorders and in the genesis of high blood pressure. In this disease inflammation results from the activity of several hematological cells as well as the presence of chemotactic factors, immunological reactivity and hyperactivity of vasoconstrictor systems as that of the renin-angiotensin. Clinical evaluation of hypertension recommends secreening of several proinflammatory substances in hypertensive patients in order to evaluate their level of cardiovascular risk. Interleukin-6 and C reactive protein have been considered the most usual risk biomarkers. Interleukin 6 is a potent proinflammatory compound which participates in the acute fase of the tissular reaction to lesions associated to immunological, ischemic or oxidative stress. C reactive protein participates during inflammation activating the first component of complement with disorganization of the phospholipidic array of the endothelial sarcolemmal membrane and the consequent endothelial dysfunction related to the genesis of high blood pressure.

REFERENCES

1. Virchow R. Cellular Pathology, Twenty Lectures. Lecture XVII (Translated by Frank Chance, B.A, M.B). John London, 1860, p393-394.

2. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 152-158.

3. Libby P, Simon DI, Rogers C: Inflammation and arterial injury. En: Topol EJ editor. Textbook of interventional cardiology 4th ed Philadelphia Elsevier Science 2003, p381-389.

4. Vázquez-Olvera G, Fernández-Real JM, Zamora A. Vilaseca M, Badimon L: Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J of Human Hypertension 2005; 19: 457-462.

5. Tillet WT, Francis T: Serological reactions in pneumonia with a nomprotein fraction of pneumococcus. J Exp Med 1930; 52: 561-571.

6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hemekens CH: Inflammation, aspirin and the resk of cardiovascular disease in apparently healthy men. New Engl J Med 1997; 336: 973-979.

7. Ridker PM: Clinical application of c reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.

8. Yeh ETH, Willerson JT: Coming of age of C-reactive protein. Using inflammation markers in cardiology. Circulation 2003; 107: 370-372.